R., Zimmermann, J
Gabe, M
Testing reveals: Whether your liver is improving, stable, or stressed If kidney function remains stable during treatment Whether blood sugar goals are being met If cardiovascular risk markers are improving Any early warning signs before symptoms appear Many people feel better on GLP-1 medications before their lab markers normalize
GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone your intestines produce in response to nutrient intake
Disclosures: Nimmy Thomas: Nothing to Disclose, Christina Stull: Nothing to Disclose, Holli Sadler: Nothing to Disclose 1056 RISK OF INCIDENT EXTRAHEPATIC CANCERS AMONG MEDICARE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) Jesse Fishman 1 Yestle Kim 1 Joe Medicis 1 Matthew Davis 2 Dominic Nunag 2 Robert Gish 3 , 1 Madrigal Pharmaceuticals, Inc., 2 Medicus Economics, LLC, 3 Robert G Gish Consultants LLC Background: NASH, or metabolic dysfunction-associated steatohepatitis (MASH), is a severe form of non-alcoholic fatty liver disease (NAFLD), or metabolic dysfunction-associated liver disease (MASLD)
Kim, D.-H., Lee, J.-C., Lee, M.-K., Kim, K.-W
